The anti-tumor activity of this component may be attributed to mechanisms involving the downregulation of SENP1, which restores the balance between SUMOylation and deSUMOylation, as well as the negative regulation of AR and c-Jun expression, thereby inhibiting AR and c-Jun mediated transcription in prostate cancer (Huang et al., 2012). The gene discussed is JUN; the disease is neoplasm.